1. Thoracic duct lymphatic fluid harbors phenotypically naive T cells for use in adoptive T-cell therapy.
- Author
-
Foster JB, Dori Y, Grupp SA, and Barrett DM
- Subjects
- Animals, Child, Cytotoxicity, Immunologic, Female, Humans, Mice, Inbred NOD, Mice, SCID, Phenotype, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen metabolism, Immunotherapy, Adoptive, Lymph cytology, T-Lymphocytes cytology, Thoracic Duct cytology
- Abstract
Background Aims: Manufacturing of potent chimeric antigen receptor (CAR) T cells requires phenotypically naive and early memory T cells. We hypothesized lymphatic fluid collected from the thoracic duct of children would serve as a unique reservoir for early T cells, which could then be used for CAR T-cell therapy., Methods: We evaluated lymphatic fluid collected from 25 pediatric patients undergoing thoracic duct cannulation for other clinical indications., Results: Lymphatic fluid in the thoracic duct was rich in T cells, with higher percentage of naive and stem central memory T-cell subsets compared with paired blood samples. T cells from lymphatic fluid showed decreased negative checkpoint regulators on the surface and increased rapid expansion with bead activation. Creation of CD19-directed CAR T cells from blood and lymphatic T cells showed similar lentiviral transduction properties, but CAR T cells generated from lymphatic fluid produced superior cytotoxicity in a murine leukemia model because they were able to achieve equivalent tumor eradication at lower doses., Conclusions: These results are the first characterization of T cells from the thoracic duct of pediatric patients and suggest an alternative approach for manufacturing of cellular therapy that will improve both expansion and cytotoxic effect., Competing Interests: Declarations of Competing Interest SAG reports grants and personal fees from Novartis; reports grants from Kite and Servier; reports personal fees from and is on advisory boards for Cellectis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Vertex, Cure Genetics, Humanigen, Roche and Cellular Biomedicine Group; and has a patent of toxicity management for anti-tumor activity of CARs (WO 2014011984 A1) issued. The other authors have no commercial, proprietary or financial interest in the products or companies described in this article., (Copyright © 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF